A change in the trend in dosulepin usage following the introduction of a prescribing indicator but not after two national safety warnings.

Autor: Deslandes PN; All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Llandough, UK.; Cardiff University School of Pharmacy and Pharmaceutical Sciences, Cardiff, UK., Jenkins KS; All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Llandough, UK., Haines KE; All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Llandough, UK., Hutchings S; All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Llandough, UK., Cannings-John R; South East Wales Trials Unit, Cardiff University, Cardiff, UK., Lewis TL, Bracchi RC; All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Llandough, UK., Routledge PA; All Wales Therapeutics and Toxicology Centre, University Hospital Llandough, Llandough, UK.; Department of Pharmacology, Therapeutics and Toxicology, Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Cardiff, UK.
Jazyk: angličtina
Zdroj: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2016 Apr; Vol. 41 (2), pp. 224-8. Date of Electronic Publication: 2016 Mar 02.
DOI: 10.1111/jcpt.12376
Abstrakt: What Is Known and Objective: The tricyclic antidepressant dosulepin has been associated with an increased risk of toxicity in overdose compared with other antidepressants. In the UK, the MHRA and NICE have issued advice on the prescribing of dosulepin, and a National Prescribing Indicator (NPI) to monitor usage was introduced in Wales in 2011. The aim of this study was to assess whether trends in dosulepin usage in Wales and NE England changed following the two pieces of safety guidance and the introduction of the National Prescribing Indicator in Wales.
Methods: Primary care dosulepin usage in the 12 months prior to and following MHRA safety advice (in 2007), NICE guideline CG90 (in 2009) and the introduction of the NPI (in 2011) was obtained. Usage was measured using defined daily doses (DDDs) per 1000 prescribing units (PUs). The trends in the 12 months prior to and following the introduction of prescribing advice and the NPI were compared using an autoregressive integrated moving average (ARIMA) model.
Results and Discussion: In Wales, the trend in dosulepin usage did not change significantly prior to and following the MHRA advice: -0·18 and -0·43 DDDs/1000PUs per month, respectively (P = 0·07), or prior to and following NICE CG90: -0·30 and -0·49 DDDs/1000PUs per month, respectively (P = 0·35). In the 12 months prior to and following the introduction of the NPI, the trend was -0·45 and -0·98 DDDs/1000PUs per month, respectively (P = 0·001). In NE England, the trend did not alter significantly following the NICE advice or the introduction of the NPI in Wales.
What Is New and Conclusion: The trend in dosulepin usage in Wales altered significantly following the introduction of the NPI, but not after the other prescribing advice. This association, coupled with the absence of a significant change in NE England over the same period, provided some evidence of the effectiveness of the NPI in prompting a change in prescribing behaviour in Wales.
(© 2016 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje